Hyperhomocysteinemia and endothelial dysfunction in patients with cerebral vascular and autoimmune diseases

Dubchenko, Ekaterina; Ivanov, Alexander; Бойко, А. Н.; Spirina, N N; Gusev, E I; Kubatiev, A. A.

doi:10.17116/jnevro2019119111133

Cited by 7 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Methionine metabolism results in the production of a mediator called homocysteine. Hyperhomocysteinemia has an extensive range of biological effects on various organs and is recognized to be associated with cardiovascular disease through different mechanisms, such as vascular dysfunction [ 107 , 108 ]. Furthermore, it has been suggested that an increased level of Hcy is pathophysiologically involved in the increased risk of MetS [ 109 ].…”

Section: Discussionmentioning

confidence: 99%

Association of baseline and changes in adiponectin, homocysteine, high-sensitivity C-reactive protein, interleukin-6, and interleukin-10 levels and metabolic syndrome incidence: Tehran lipid and glucose study

Zahedi,

Daneshpour,

Akbarzadeh

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Association of baseline and changes in adiponectin, homocysteine, high-sensitivity C-reactive protein, interleukin-6, and interleukin-10 levels and metabolic syndrome incidence: Tehran lipid and glucose study

Zahedi,

Daneshpour,

Akbarzadeh

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Hyperhomocysteinemia (HHcy) stands as a well-established independent risk factor for cardiovascular and cerebrovascular diseases ( Dubchenko et al, 2019 ). Hence, understanding the potential pathophysiological interplay between Hcy levels and MetS is of paramount’ importance.…”

Section: Potential Mechanisms Linking Nnmt To Metsmentioning

confidence: 99%

Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome

Sun,

Zhu,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Metabolic syndrome (MetS) represents a constellation of metabolic abnormalities, typified by obesity, hypertension, hyperglycemia, and hyperlipidemia. It stems from intricate dysregulations in metabolic pathways governing energy and substrate metabolism. While comprehending the precise etiological mechanisms of MetS remains challenging, evidence underscores the pivotal roles of aberrations in lipid metabolism and insulin resistance (IR) in its pathogenesis. Notably, nicotinamide N-methyltransferase (NNMT) has recently surfaced as a promising therapeutic target for addressing MetS. Single nucleotide variants in the NNMT gene are significantly correlated with disturbances in energy metabolism, obesity, type 2 diabetes (T2D), hyperlipidemia, and hypertension. Elevated NNMT gene expression is notably observed in the liver and white adipose tissue (WAT) of individuals with diabetic mice, obesity, and rats afflicted with MetS. Knockdown of NNMT elicits heightened energy expenditure in adipose and hepatic tissues, mitigates lipid accumulation, and enhances insulin sensitivity. NNMT catalyzes the methylation of nicotinamide (NAM) using S-adenosyl-methionine (SAM) as the donor methyl group, resulting in the formation of S-adenosyl-l-homocysteine (SAH) and methylnicotinamide (MNAM). This enzymatic process results in the depletion of NAM, a precursor of nicotinamide adenine dinucleotide (NAD+), and the generation of SAH, a precursor of homocysteine (Hcy). Consequently, this cascade leads to reduced NAD+ levels and elevated Hcy levels, implicating NNMT in the pathogenesis of MetS. Moreover, experimental studies employing RNA interference (RNAi) strategies and small molecule inhibitors targeting NNMT have underscored its potential as a therapeutic target for preventing or treating MetS-related diseases. Nonetheless, the precise mechanistic underpinnings remain elusive, and as of yet, clinical trials focusing on NNMT have not been documented. Therefore, further investigations are warranted to elucidate the intricate roles of NNMT in MetS and to develop targeted therapeutic interventions.

show abstract

“…В настоящее время гипергомоцистеинемия рассматривается в качестве одного из важнейших модифицируемых факторов риска развития ССЗ [54]. У больных системной склеродермией и анкилозирующим спондилоартритом уровень ГЦ существенно превышал таковой у пациентов с ревматоидным артритом.…”

Section: маркеры эндотелиальной дисфункцииunclassified

Overview of metabolomic markers used for diagnosing cardiovascular diseases

Astafyeva

Zharkov

Ясенявская

et al. 2022

Sibirskij nauchnyj medicinskij zhurnal

View full text Add to dashboard Cite

At present, metabolomics is an intensively developing approach to the specific diagnosis of cardiovascular diseases. Metabolic analysis allows the study of complete metabolomic profiles and their deviations resulting from changes, for example, gene and RNA expression, protein activity, or environmental factors. Analysis of the metabolomic blood profile helps in solving a large number of scientific and clinical problems, one of which is the search for markers of diseases, in particular, cardiovascular diseases (CVD). Aim of the study was to investigate metabolomic markers used for the diagnosis of cardiovascular diseases on the basis of literature data. Material and methods. The literature data was analyzed for key words: cardiovascular diseases, metabolomics, metabolic profile, metabolomic markers in da- tabases PubMed, Scopus, Web of Science, CyberLeninka, PatentDB, Science Direct Open Access, eLibrary. Results. Analysis of literature data and patent search confirms the high importance of metabolomic markers in the diagnosis of CVD. In the patent literature, BNP/NT-proBNP is most common used as a metabolic marker of CVD (11.27 %). The use of CRP (8.99 %) and troponin (8.49 %) is also common. PICP (0.02 %), sVCAM-1 (0.09 %), stimulating growth factor ST-2 (0.12 %) and thrombomodulin (0.12 %) as metabolic markers of CVD. Conclusions. Against the backdrop of analytical methods, metabolomics is the most important diagnostic area. At the same time, it should be noted that by combining the results of the analysis of metabolic studies with others, for example, genomic and proteomic, one can get a complete picture of the pathogenesis of diseases, assess the risk of complications, and also determine the effectiveness of the treatment.

show abstract

Hyperhomocysteinemia and endothelial dysfunction in patients with cerebral vascular and autoimmune diseases

Cited by 7 publications

References 57 publications

Association of baseline and changes in adiponectin, homocysteine, high-sensitivity C-reactive protein, interleukin-6, and interleukin-10 levels and metabolic syndrome incidence: Tehran lipid and glucose study

Association of baseline and changes in adiponectin, homocysteine, high-sensitivity C-reactive protein, interleukin-6, and interleukin-10 levels and metabolic syndrome incidence: Tehran lipid and glucose study

Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome

Overview of metabolomic markers used for diagnosing cardiovascular diseases

Contact Info

Product

Resources

About